Cargando…
Evidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data from the US Food and Drug Administration Adverse Event Reporting System
INTRODUCTION: Sodium oxybate has been approved by the US Food and Drug Administration (FDA) to treat narcolepsy for 20 years; however, the only available products have been immediate-release (IR) formulations given twice nightly—once at bedtime and a second dose 2.5–4 h later—creating inherent risks...
Autores principales: | Gudeman, Jennifer, Burroughs, Danielle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232711/ https://www.ncbi.nlm.nih.gov/pubmed/36662389 http://dx.doi.org/10.1007/s40801-023-00351-9 |
Ejemplares similares
-
Psychosis in Patients with Narcolepsy as an Adverse Effect of Sodium Oxybate
por: Sarkanen, Tomi, et al.
Publicado: (2014) -
Sleep, Narcolepsy, and Sodium Oxybate
por: Mamelak, Mortimer
Publicado: (2022) -
Sodium Oxybate: a Substitute for Alcohol?
por: Gual, A., et al.
Publicado: (2022) -
Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment
por: Morse, Anne Marie, et al.
Publicado: (2023) -
Response to: Once-nightly sodium oxybate (FT218) in the treatment of
narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et
al
por: Kushida, Clete A, et al.
Publicado: (2022)